Clinical trial

Study of Maintenance of the Efficiency and Adverse Effects of Pharmacological Treatments in Sex Offenders With Paraphilia

Name
P150962J
Description
This research concerns the evaluation of the maintenance of the efficiency and incidence of adverse effects of pharmacological treatments in sex offenders with paraphilia. Despite the increasing use of pharmacological treatments in these indications, there are few data to indicate which sex offender populations benefit from which pharmacological treatments and which adverse events are observed, particularly with anti-androgens or antidepressant treatments that are widely used in these subjects. A recent Cochrane study showed that psychodynamic treatment is less effective in terms of sexual delinquency compared to probation alone and has not shown significant efficacy of cognitive behavioral therapy (CBT) compared to the lack of treatment, except for a study in which anti-androgen therapy was associated with CBT. Another recent study concluded that the tolerance, even of anti-androgenic drugs, was uncertain, as all studies were small and of limited duration, and new research is needed in the future. Further research demonstrating the efficacy of SSRIs in the treatment of paraphilic disorders is still needed and long-term studies are lacking. Their use for this indication is still off label. As far as we know, this cohort should be the largest population of paraphilic sex offenders studied for the longest time to date in a field where research is insufficient. This large sample receiving routine care and followed for 3 years should allow to analyse the maintenance of the effectiveness of the pharmacological treatments received (SSRIs or anti-androgens), and their tolerance. In addition, this analysis of clinical practices should be crucial to improve the knowledge of the indications for these treatments, which could possibly be reviewed with respect to their effectiveness and tolerance, especially in the most serious cases of paraphilic sex offenders.
Trial arms
Trial start
2023-06-01
Estimated PCD
2026-12-01
Trial end
2027-10-01
Status
Not yet recruiting
Treatment
Evaluation Scales
* PATHOS / PEACCE : hypersexuality diagnostic scale * PDQ-4+: Personality Diagnostic Questionnaire version 4 * AUDIT * Life trajectory : THQ * Cognitive function (MoCA, Stroop) * ISDSS: and self report of sexual activity and desire * BARS: Brief Adhesion Rating Scale (treatment observance) * SF-36 scale : quality of life * BDI-II : Beck Depression Inventory * BSSI ; Beck suicidal Inventory * Cognitive functioning evaluation : Molest and Rape Scale * Empathy: EMPAT * Evaluation of Cognitive functioning: denial evaluation and Mc Kibben minimization * Baratt Impulsivity Scale * CSBI * Static 99 and Stable 2007
Arms:
Anti-androgen Group, No SSRIs or antiandrogen treatment at inclusion, SSRI Group
osteodensitometry
Osteodensitometry
Arms:
Anti-androgen Group, No SSRIs or antiandrogen treatment at inclusion, SSRI Group
blood samples
* Lipid profile (total cholesterol, triglycerides, HDL cholesterol) * Liver function (ASAT, ALAT, total bilirubin, transferase gamma-glutamyl et alcalin phosphatases * Kydney function * Blood count * Biological Measurements and Measurement of Systematic Plasma Testosterone and TeBG Levels in Sex Offenders check for pathology of the Gonadotropin Axis * Biological Measurements of Plasma Prolactin level
Arms:
Anti-androgen Group, No SSRIs or antiandrogen treatment at inclusion, SSRI Group
ECG
ECG (heart rate, search for cardiac conduction disorders or cardiac arrhythmias)
Arms:
Anti-androgen Group, No SSRIs or antiandrogen treatment at inclusion, SSRI Group
Blood and saliva samples
Blood and saliva samples
Arms:
Anti-androgen Group, No SSRIs or antiandrogen treatment at inclusion, SSRI Group
Size
250
Primary endpoint
Sexual desire and activity intensity scale
Change from inclusion at 36 months
Incidence of adverse events
36 months
Eligibility criteria
Inclusion Criteria: Man * At least one sex offence * Paraphilia (DSM-5 criteria ) * Receiving pharmacological treatment ( ISRS or anti-androgen or none of them) * Age between 18 and 65 years * Patient 100% covered by social security Exclusion Criteria: * no consent * female * aged under 18 or over 65 years * subject receiving simultaneous ISRS and anti-androgen treatment before enrolment * incarcerated * Subject under guardianship (patients under curatorship may however be included), * no social security registration * contraindications or allergies to treatments
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 250, 'type': 'ESTIMATED'}}
Updated at
2023-02-13

1 organization

2 products

1 indication

Indication
Paraphilias